Clarus Ventures and Novo A/S back Nuvelution

Clarus Ventures and Novo A/S have provided an undisclosed investment in Nuvelution Pharma Inc. In addition to the funding, Nuvelution has named Dr. Barry Gertz and Dr. James Cornwall as chief physician scientist and chief business officer, respectively. Based in South San Francisco, Nuvelution is a solutions provider for R&D companies in the pharmaceutical and biotech industries to improve their productivity.

Annexon Bioscience racks up $34 mln

Annexon Bioscience has raised $34 million in Series A-1 funding. Novartis Venture Funds led the round with participation from Satter Investment Management and Clarus Ventures. Based in Redwood City, Calif., Annexon Bioscience is a developer of pathway inhibitors that treat neurodegenerative and autoimmune diseases.


Flowonix Medical nabs about $40 mln

Flowonix Medical has secured about $40 million in funding. The investors included Élevage Capital Management, Clarus Ventures and Hercules Technology Growth Capital. Based in NJ and Mass., Flowonix is a provider of implantable drug delivery solutions.

Imago BioSciences fetches $26.5 mln Series A

San Francisco-based biotech firm Imago BioSciences has closed $26.5 million in Series A funding. Clarus Ventures led the round with participation from other investors that included Frazier Healthcare, Amgen Ventures and Merck Research Labs Venture Fund. In conjunction with the funding, representatives from Clarus Ventures and Frazier Healthcare have been added to the the company’s board of directors.


Breast implants seller Sientra debuts IPO

Santa Barbara, Calif-based Sientra, a seller of breast implants, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “SIEN.” Piper Jaffray and Stifel are serving as lead underwriters. Sientra’s backers include OrbiMed Advisors, Clarus Ventures, Abingworth Management, Goldman Sachs and TIAA-CREF.

Heptares Attracts $21m for Clinical Development

Drug discovery and development company Heptares Therapeutics has raised over $21 million in a Series B financing. The round was co-led by the Stanley Family Foundation and current investor Clarus Ventures with Takeda Ventures also participating.

NanoString Technologies Prices IPO; VC firms Clarus, DFJ and OVP Poised for Payout

Venture-backed NanoString Technologies Inc. on Tuesday said that it is pricing its initial public offering of 5.4 million shares at $10 per share. The company, which makes life science tools for translational research and molecular diagnostic products, has raised a total of $82 million in venture capital since its founding in 2003. Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners as a group own 7.4 million pre-IPO shares, or 79% of the company, according to its S-1 filing.

Boston-Based Firm Launches Eventide Healthcare & Life Sciences Fund

Eventide Asset Management, a Boston-based investment advisory firm that is “committed to biblically responsible investing,” has launched a new fund, the Eventide Healthcare & Life Sciences. The fund’s lead portfolio manager is Finny Kuruvilla, who also serves as a principal at the healthcare venture capital firm Clarus Ventures.

NanoString Technologies Completes Series E

NanoString Technologies, a provider of life science tools for translational research and developer of molecular diagnostic products, has completed a $15.3 million Series E Preferred Stock issuance. New investors in the transaction included Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group. All previous venture investors participated including Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures, and Henri Termeer.

NanoString Technologies Appoints New CFO

NanoString Technologies, a provider of life science tools and developer of molecular diagnostics, has appointed James A. Johnson as the company’s new chief financial officer. Johnson assumes this role from Wayne Burns who will remain with the company in his new position as senior vice president, operations and administration. NanoString Technologies is backed by GE, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

Catabasis Pharma Bags $8M More for Series A

Massachusetts-based Catabasis Pharmaceuticals raised an additional $8 million in its Series A financing, now bringing its total funding for the round to $47.6 million. The company is developing an omega-3 conjugated compound for patients with severe hypertriglyceridemia. SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures all participated in the funding.

NanoString Inks $20M Series D

Seattle-based NanoString Technologies, a provider of tools for translational research and developer of molecular diagnostics, has raised $20 million in Series D financing. New investors include GE; BioMed Ventures; and Henri Termeer, the former chief executive of Genzyme Corp. All previous venture investors in NanoString also participated in the financing, including Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners, the company said.

Cleave Biosciences Raises $42M Series A

Cleave Biosciences has raised $42 million in venture capital to develop new treatments for cancer. The Series A round investors include U.S. Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management. The financing will support multiple small molecule discovery and development programs in the area of protein homeostasis, the company said.

Restoration Robotics Seals $41M

Restoration Robotics, a medical device company focused on hair restoration, has closed a $41 million Series C round led by Clarus Ventures. Sutter Hill Ventures, Alloy Ventures and Interwest Partners also joined in the round, which will be used for commercialization and the launch of its technology. The company is making computer-assisted technology that enables harvesting of hair follicles during hair restoration procedures.

Slideshow: CalPERS’ 2008 Banner Year for Venture: Top Commitments and Current IRRs

CalPERS ratcheted up its venture capital commitments as better economic conditions returned in the middle of the last decade. This culminated in the banner year of 2008, when the California Public Employees’ Retirement System put about $1.27 billion into 23 funds, according to peHUB’s evaluation of the investment data updated through Dec. 31. The decision […]

Slideshow: CalPERS’ Mid-Decade Venture Boom — Commitments Jumped in 2006-08

CalPERS, like many LPs, turned hesitant toward venture during the recent global recession. But the pension fund followed more free spending ways just prior to the slowdown, with commitments in 2006, 2007 and 2008 doubling or more. These mid-decade vintage years saw the California Public Employees’ Retirement System — the nation’s largest public pension fund […]

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget